Liquid Biopsy in Advanced Prostate Cancer
Blood tests identify cancer-driving gene mutations in advanced prostate cancer, guiding precision therapies, though distinguishing true mutations from blood cell noise remains challenging.
This review summarizes the current landscape of liquid biopsy in advanced prostate cancer, emphasizing the clinical utility of ctDNA for actionable mutation detection (BRCA1/2, ATM) guiding PARP inhibitor therapy and emerging approaches including fragmentomics and methylation profiling for improved specificity. The authors highlight clonal hematopoiesis as an underappreciated source of false-positive cfDNA findings requiring awareness in clinical practice.
What the study was
- Study design
- Narrative review
- Population
- Advanced prostate cancer patients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Cancers (Basel)
Why it surfaced
Practical review of a high-volume clinical topic; clonal hematopoiesis confounder discussion adds clinical value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.